Elevated Stratifin promotes cisplatin-based chemotherapy failure and poor prognosis in non-small cell lung cancer

Elevated Stratifin promotes cisplatin-based chemotherapy failure and poor prognosis in non-small cell lung cancer

Drug resistance is a key factor in the treatment failure of clinical non-small cell lung cancer (NSCLC) patients after adjuvant chemotherapy. Here, our results provide the first evidence that eukaryotic translation initiation factor 2b subunit delta (EIF2B4)-Stratifin (SFN) fusion and increased SFN...

Full description

Bibliographic Details
Main Authors: Yu-Shui Ma, Li-Kun Hou, Shi-Hua Yao, Ji-Bin Liu, Xue-Chen Yu, Yi Shi, Xiao-Li Yang, Wei Wu, Chun-Yan Wu, Geng-Xi Jiang, Da Fu
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Molecular Therapy: Oncolytics
Subjects:
SFN
NSCLC
GEO database
ACT
prognostic biomarker
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770521001029

Internet

http://www.sciencedirect.com/science/article/pii/S2372770521001029

Similar Items